Published in J Virol on April 01, 1986
Pathogenesis and molecular biology of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev (1992) 3.32
Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev (2012) 2.92
The Epstein-Barr virus (EBV) BZLF1 immediate-early gene product differentially affects latent versus productive EBV promoters. J Virol (1989) 2.65
An Epstein-Barr virus immediate-early gene product trans-activates gene expression from the human immunodeficiency virus long terminal repeat. Proc Natl Acad Sci U S A (1988) 2.20
Human herpes virus-6 increases HIV-1 expression in co-infected T cells via nuclear factors binding to the HIV-1 enhancer. EMBO J (1989) 1.88
The Epstein-Barr virus immediate-early gene product, BMLF1, acts in trans by a posttranscriptional mechanism which is reporter gene dependent. J Virol (1989) 1.86
Trans-activation of the JC virus late promoter by the tat protein of type 1 human immunodeficiency virus in glial cells. Proc Natl Acad Sci U S A (1990) 1.52
The transcriptional enhancer element, kappa B, regulates promoter activity of the human neurotropic virus, JCV, in cells derived from the CNS. Nucleic Acids Res (1993) 1.20
Molecular regulation of JC virus tropism: insights into potential therapeutic targets for progressive multifocal leukoencephalopathy. J Neuroimmune Pharmacol (2010) 1.08
A novel sequence-specific DNA-binding protein, LCP-1, interacts with single-stranded DNA and differentially regulates early gene expression of the human neurotropic JC virus. J Virol (1992) 1.08
Evidence that a sequence similar to TAR is important for induction of the JC virus late promoter by human immunodeficiency virus type 1 Tat. J Virol (1992) 0.96
Transcription factor Spi-B binds unique sequences present in the tandem repeat promoter/enhancer of JC virus and supports viral activity. J Gen Virol (2010) 0.96
Progressive multifocal leukoencephalopathy-associated mutations in the JC polyomavirus capsid disrupt lactoseries tetrasaccharide c binding. MBio (2013) 0.95
JC polyomavirus attachment, entry, and trafficking: unlocking the keys to a fatal infection. J Neurovirol (2014) 0.89
Unusual DNA structure in the regulatory region of the human papovavirus JC virus. J Virol (1988) 0.86
Mapping 5' termini of JC virus early RNAs. J Virol (1986) 0.86
A new method for sequencing DNA. Proc Natl Acad Sci U S A (1977) 250.51
Purification of biologically active globin messenger RNA by chromatography on oligothymidylic acid-cellulose. Proc Natl Acad Sci U S A (1972) 83.88
Sizing and mapping of early adenovirus mRNAs by gel electrophoresis of S1 endonuclease-digested hybrids. Cell (1977) 61.24
DNA-dependent transcription of adenovirus genes in a soluble whole-cell extract. Proc Natl Acad Sci U S A (1980) 24.21
Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet (1971) 11.92
Human polyomavirus JC virus genome. J Virol (1984) 5.87
Activation of the SV40 late promoter: direct effects of T antigen in the absence of viral DNA replication. Cell (1984) 5.30
Mapping the spliced and unspliced late lytic SV40 RNAs. Cell (1978) 4.25
Transcription maps of adenovirus. Methods Enzymol (1980) 3.82
The 5'-terminal leader sequence of late 16 S mRNA from cells infected with simian virus 40. J Biol Chem (1978) 3.60
Establishment of a line of human fetal glial cells that supports JC virus multiplication. Proc Natl Acad Sci U S A (1985) 2.93
JC virus, a human polyomavirus associated with progressive multifocal leukoencephalopathy: additional biological characteristics and antigenic relationships. Infect Immun (1977) 2.57
JC virus enhancer-promoter active in human brain cells. Science (1984) 2.36
Site-specific base substitution and deletion mutations that enhance or suppress transcription of the SV40 major late RNA. Cell (1982) 2.32
JC Papovavirus in progressive multifocal leukoencephalopathy. J Infect Dis (1976) 1.93
Localization of the 5' terminus of late SV40 mRNA. Nucleic Acids Res (1978) 1.80
Characterization of tissue culture-induced heterogeneity in DNAs of independent isolates of JC virus. J Gen Virol (1983) 1.12
Preferential stimulation of transcription from simian virus 40 late and adeno IVa2 promoters in a HeLa cell extract. J Biol Chem (1983) 1.08
Characterization of a surrogate TATA box promoter that regulates in vitro transcription of the simian virus 40 major late gene. Mol Cell Biol (1985) 1.03
Transfection of human fetal glial cells with molecularly cloned JCV DNA. Prog Clin Biol Res (1983) 1.02
New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst (1990) 23.46
The reservoir for HIV-1 in human peripheral blood is a T cell that maintains expression of CD4. Science (1989) 7.90
Structure of replicating simian virus 40 deoxyribonucleic acid molecules. J Virol (1971) 6.74
Origin and direction of simian virus 40 deoxyribonucleic acid replication. J Virol (1972) 6.39
HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci U S A (1999) 5.25
Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study. N Engl J Med (1995) 4.06
Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J Virol (1997) 3.64
Intermediate in SV40 DNA chain growth. Nat New Biol (1972) 3.38
Epstein-Barr viral latency is disrupted by the immediate-early BRLF1 protein through a cell-specific mechanism. Proc Natl Acad Sci U S A (1996) 3.13
Resolutions and identification of the core deoxynucleoproteins of the simian virus 40. Biochem Biophys Res Commun (1973) 2.90
Sequential protein synthesis following vaccinia virus infection. J Virol (1968) 2.89
EBNA-2 transactivates a lymphoid-specific enhancer in the BamHI C promoter of Epstein-Barr virus. J Virol (1991) 2.70
Increasing viral burden in CD4+ T cells from patients with human immunodeficiency virus (HIV) infection reflects rapidly progressive immunosuppression and clinical disease. Ann Intern Med (1990) 2.65
Morphological and immunocytochemical characteristics of human tumor cell lines for use in a disease-oriented anticancer drug screen. Anticancer Res (1992) 2.62
Integrated proviral human immunodeficiency virus type 1 is present in CD4+ peripheral blood lymphocytes in healthy seropositive individuals. J Virol (1989) 2.62
Application of branched DNA signal amplification to monitor human immunodeficiency virus type 1 burden in human plasma. J Infect Dis (1994) 2.60
The Epstein-Barr virus (EBV) BMRF1 promoter for early antigen (EA-D) is regulated by the EBV transactivators, BRLF1 and BZLF1, in a cell-specific manner. J Virol (1990) 2.49
Inhibition in the joining of DNA intermediates to growing simian virus 40 chains. J Virol (1973) 2.44
JC virus enhancer-promoter active in human brain cells. Science (1984) 2.36
Sequential formation of vaccinia virus proteins and viral deoxyribonucleic acid replication. J Virol (1967) 2.34
Site-specific base substitution and deletion mutations that enhance or suppress transcription of the SV40 major late RNA. Cell (1982) 2.32
Parallel evolution of drug resistance in HIV: failure of nonsynonymous/synonymous substitution rate ratio to detect selection. Mol Biol Evol (1999) 2.32
Impact of HIV-1 infection and highly active antiretroviral therapy on the kinetics of CD4+ and CD8+ T cell turnover in HIV-infected patients. Proc Natl Acad Sci U S A (2000) 2.20
Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. Blood (2000) 2.15
HIV-1 replication in patients with undetectable plasma virus receiving HAART. Highly active antiretroviral therapy. Lancet (1999) 2.13
Functional and physical interaction between p53 and BZLF1: implications for Epstein-Barr virus latency. Mol Cell Biol (1994) 2.12
Epstein-barr virus immediate-early protein BZLF1 is SUMO-1 modified and disrupts promyelocytic leukemia bodies. J Virol (2001) 2.07
Human immunodeficiency virus type 1 quasi species that rebound after discontinuation of highly active antiretroviral therapy are similar to the viral quasi species present before initiation of therapy. J Infect Dis (2000) 1.96
Lysophosphatidic acid is detectable in human bronchoalveolar lavage fluids at baseline and increased after segmental allergen challenge. Clin Exp Allergy (2007) 1.94
Simian virus 40 major late promoter: an upstream DNA sequence required for efficient in vitro transcription. Mol Cell Biol (1984) 1.94
Epstein-Barr virus immediate-early proteins BZLF1 and BRLF1 activate the ATF2 transcription factor by increasing the levels of phosphorylated p38 and c-Jun N-terminal kinases. J Virol (2000) 1.77
N-acylated glycerophospholipids and their derivatives. Prog Lipid Res (1990) 1.77
Metabolic properties of early and late vaccinia virus messenger ribonucleic acid. J Virol (1967) 1.70
Specific initiation site for simian virus 40 deoxyribonucleic acid replication. J Virol (1972) 1.66
NADPH oxidase is required for the sensory plasticity of the carotid body by chronic intermittent hypoxia. J Neurosci (2009) 1.65
Angioplasty and bolus urokinase infusion for the restoration of function in thrombosed Brescia-Cimino dialysis fistulas. J Vasc Interv Radiol (1999) 1.58
Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda. HIV Med (2007) 1.58
Biosynthesis and processing of human immunodeficiency virus type 1 envelope glycoproteins: effects of monensin on glycosylation and transport. J Virol (1989) 1.53
Simian virus 40 guanine-cytosine-rich sequences function as independent transcriptional control elements in vitro. Mol Cell Biol (1984) 1.52
The HIV-1 gp120 envelope protein has the intrinsic capacity to stimulate monokine secretion. J Immunol (1991) 1.51
Involvement of c-Src in diperoxovanadate-induced endothelial cell barrier dysfunction. Am J Physiol Lung Cell Mol Physiol (2000) 1.51
Envelope-specific antibodies in the saliva of individuals vaccinated with recombinant HIV-1 gp160. J Acquir Immune Defic Syndr (1992) 1.49
Expression of protein kinase C isozymes in nonpregnant and pregnant human myometrium. Am J Obstet Gynecol (2000) 1.46
Functional and physical interactions between the Epstein-Barr virus (EBV) proteins BZLF1 and BMRF1: Effects on EBV transcription and lytic replication. J Virol (1996) 1.44
Unwinding of parental strands during simian virus 40 DNA replication. J Virol (1973) 1.43
The SV40 DNA template for transcription of late mRNA in viral nucleoprotein complexes. Cell (1977) 1.42
The Epstein-Barr virus BZLF1 protein interacts physically and functionally with the histone acetylase CREB-binding protein. J Virol (1999) 1.41
Functional impairment of bronchoalveolar lavage phospholipids in early Pneumocystis carinii pneumonia in rats. J Lab Clin Med (1996) 1.41
Characterization of Simian virus 40 DNA component II during viral DNA replication. J Mol Biol (1973) 1.40
Molecular cloning and predicted full-length amino acid sequence of the type I beta isozyme of cGMP-dependent protein kinase from human placenta. Tissue distribution and developmental changes in rat. FEBS Lett (1989) 1.39
Biochemical changes in phytohemagglutinin stimulated human lymphocytes. Exp Cell Res (1966) 1.39
In vitro transcription initiation by purified RNA polymerase II within the adenovirus 2 major late promoter region. J Biol Chem (1984) 1.38
Occurrence and properties of a chromatin-associated F1-histone phosphokinase in mitotic Chinese hamster cells. Biochemistry (1972) 1.38
Passive hemagglutination test for detection of antibodies to human immunodeficiency virus type 1 and comparison of the test with enzyme-linked immunosorbent assay and Western blot (immunoblot) analysis. J Clin Microbiol (1989) 1.36
The N-acylation-phosphodiesterase pathway and cell signalling. Chem Phys Lipids (1996) 1.35
Superhelix density of replicating simian virus 40 DNA molecules. J Mol Biol (1974) 1.34
Interstitial hyperosmolarity may cause axis cylinder shrinkage in streptozotocin diabetic nerve. J Neuropathol Exp Neurol (1980) 1.31
Chemical modification of simian virus 40 DNA by reaction with a water-soluble carbodiimide. J Virol (1976) 1.31
Proximal and distal domains that control in vitro transcription of the adenovirus IVa2 gene. Proc Natl Acad Sci U S A (1984) 1.30
Prevention of the spread of HIV-1 infection with nonnucleoside reverse transcriptase inhibitors. Virology (1992) 1.29
Mapping of transcription sites of simian virus 40-specific late 16S and 19S mRNA by electron microscopy. Proc Natl Acad Sci U S A (1977) 1.28
N-Acylethanolamine accumulation in infarcted myocardium. Biochem Biophys Res Commun (1979) 1.27
Characterization of the human gene encoding the type I alpha and type I beta cGMP-dependent protein kinase (PRKG1). Genomics (1997) 1.27
RAZ, an Epstein-Barr virus transdominant repressor that modulates the viral reactivation mechanism. J Virol (1994) 1.27
Epstein-Barr virus immediate-early protein BRLF1 induces the lytic form of viral replication through a mechanism involving phosphatidylinositol-3 kinase activation. J Virol (2001) 1.27
Regulation of endothelial cell myosin light chain kinase by Rho, cortactin, and p60(src). Am J Physiol (1999) 1.26
Factors involved in specific transcription by mammalian RNA polymerase II. Role of factors IID and MLTF in transcription from the adenovirus major late and IVa2 promoters. J Biol Chem (1989) 1.26
Properties of simian virus 40 transcriptional intermediates isolated from nuclei of permissive cells. J Virol (1977) 1.25
Persistence of four related human immunodeficiency virus subtypes during the course of zidovudine therapy: relationship between virion RNA and proviral DNA. J Virol (1994) 1.25
Pulmonary endothelial cell barrier enhancement by FTY720 does not require the S1P1 receptor. Cell Signal (2007) 1.24
Synthesis and processing of human immunodeficiency virus type 1 envelope proteins encoded by a recombinant human adenovirus. J Virol (1989) 1.21
Peripheral expansion of pre-existing mature T cells is an important means of CD4+ T-cell regeneration HIV-infected adults. Nat Med (1998) 1.21
Efficient transcription of a compact nucleoprotein complex isolated from purified simian virus 40 virions. J Virol (1980) 1.21
Studies of polyoma virus DNA: cleavage map of the polyoma virus genome. J Virol (1975) 1.20
Characterization of simian virus 40 tsA58 transcriptional intermediates at restrictive temperatures: relationship between DNA replication and transcription. J Virol (1977) 1.20
Metabolism of N-acylethanolamine phospholipids by a mammalian phosphodiesterase of the phospholipase D type. J Biol Chem (1983) 1.20
The Zif268 cellular transcription factor activates expression of the Epstein-Barr virus immediate-early BRLF1 promoter. J Virol (1995) 1.15
Regulation of simian virus 40 early and late gene transcription without viral DNA replication. J Virol (1979) 1.14
Separation of isolated Chinese hamster metaphase chromosomes into three size-groups. J Mol Biol (1968) 1.14
N-Acylation of ethanolamine phospholipids in canine myocardium. Biochim Biophys Acta (1982) 1.12
Accumulation of N-acylethanolamine glycerophospholipids in infarcted myocardium. Biochim Biophys Acta (1980) 1.12
F1-histone modification at metaphase in Chinese hamster cells. Exp Cell Res (1972) 1.11
Disparate effects of two herpesvirus [corrected] immediate-early gene trans-activators on the HIV-1 LTR. Virology (1989) 1.11
Synthetic analogs of FTY720 [2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol] differentially regulate pulmonary vascular permeability in vivo and in vitro. J Pharmacol Exp Ther (2009) 1.11
Characterization of the 5'-terminal structure of simian virus 40 early mRNA's. J Virol (1979) 1.10
Hin D restriction mapping of upaired regions in simian virus 40 superhelical DNA I: considerations regarding structure-function relationships. J Virol (1976) 1.10
Preferential stimulation of transcription from simian virus 40 late and adeno IVa2 promoters in a HeLa cell extract. J Biol Chem (1983) 1.08
Retinoic acid is a negative regulator of the Epstein-Barr virus protein (BZLF1) that mediates disruption of latent infection. Proc Natl Acad Sci U S A (1993) 1.07
Diperoxovanadate alters endothelial cell focal contacts and barrier function: role of tyrosine phosphorylation. J Appl Physiol (1985) (2000) 1.07
The cellular YY1 transcription factor binds a cis-acting, negatively regulating element in the Epstein-Barr virus BRLF1 promoter. J Virol (1997) 1.06
Catabolism of N-acylethanolamine phospholipids by dog brain preparations. J Neurochem (1984) 1.05
Subclinical central nervous system infection with JC virus in patients with AIDS. J Infect Dis (1992) 1.04